Education
About Us
Working with TipRanks
Follow Us
Nkarta (NKTX)
NASDAQ:NKTX
NKTX Stock Chart & Stats
$1.87
-$0.05(-2.07%)
At close: 4:00 PM EST
$1.87
-$0.05(-2.07%)
Day’s Range― - ―
52-Week Range$1.31 - $3.16
Previous CloseN/A
Volume369.36K
Average Volume (3M)1.16M
Market Cap
$132.83M
Enterprise Value-$52.47M
Total Cash (Recent Filing)$282.33M
Total Debt (Recent Filing)$76.63M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Nov 05, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,029,510
10 Day Avg. Volume736,145
30 Day Avg. Volume1,155,886
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap-0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$12.75Price Target Upside581.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressNkarta is preparing for preliminary data from Ntrust-1 and Ntrust-2 clinical trials, which will provide the first look at the efficacy of NKX019 for treating various autoimmune diseases.
Financial PositionNkarta's strong cash position of $316.5M at the end of 3Q:25 allows for strategic flexibility.
Regulatory ApprovalThe FDA has approved the elimination of the patient-by-patient stagger requirement, allowing for quicker enrollment and dose escalation in trials.
Bears Say
Data Timing DelaysThe company has delayed its data timing guidance from 4Q25 to a medical meeting in 2026.
Financial PerformanceFor the third quarter, Nkarta reported a net loss of $21.7 million, or $0.29 per share.
Market CompetitionWithout a reduced lymphodepletion regimen, it is increasingly challenging to discern how NKX019 may be differentiated from other CD19 allogeneic cell therapies in the increasingly competitive market.
Nkarta News
NKTX FAQ
What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $1.31 and its highest was $3.15 in the past 12 months.
What is Nkarta’s market cap?
Nkarta’s market cap is $132.83M.
When is Nkarta’s upcoming earnings report date?
Nkarta’s upcoming earnings report date is Nov 05, 2025 which is 12 days ago.
How were Nkarta’s earnings last quarter?
Nkarta released its earnings results on Nov 10, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.015.
Is Nkarta overvalued?
According to Wall Street analysts Nkarta’s price is currently Undervalued.
Does Nkarta pay dividends?
Nkarta does not currently pay dividends.
What is Nkarta’s EPS estimate?
Nkarta’s EPS estimate is -0.31.
How many shares outstanding does Nkarta have?
Nkarta has 71,029,510 shares outstanding.
What happened to Nkarta’s price movement after its last earnings report?
Nkarta reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went up 2.551%.
Which hedge fund is a major shareholder of Nkarta?
Currently, no hedge funds are holding shares in NKTX
Nkarta Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (581.82% Upside)
$12.75 (581.82% Upside)
Blogger Sentiment
Bullish
NKTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.74%
12-Months-Change
Fundamentals
Return on Equity
-26.69%
Trailing 12-Months
Asset Growth
-19.70%
Trailing 12-Months
Company Description
Nkarta
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX Stock 12 Month Forecast
Average Price Target
$12.75
▲(581.82% Upside)
Technical Analysis
Ownership Overview
21.28% Insiders
8.37% Mutual Funds
0.03% Other Institutional Investors
64.04% Public Companies and
Individual Investors